Monogram Orthopaedics reports 2023 EPS (61c) vs. ($1.42) last year

Reports revenue $364,999 vs. $0 last year. “2023 was transformative for Monogram as our first year as a public company, with a focus on advancing our product launch for mBos and the continued development of our next-gen product pipeline,” said Ben Sexson, Chief Executive Officer of Monogram. “The fourth quarter was highlighted by the delivery of our first mBos surgical robot to one of the world’s largest global robotics distributors and the introduction of mVision technology…Looking ahead into 2024, our next milestones on the commercialization path include completing our verification and validation testing, submitting mBos to the FDA for clearance, and obtaining approvals to run our OUS clinical trial. We will also further develop our mVision navigation technology, which could become a standalone product and/or be integrated into mBos. Taken together, we are incredibly enthusiastic about the future for Monogram, the pace of our product timeline, and our team’s ability to scale the commercialization path of our advanced, next-generation active surgical robotics,” concluded Sexson.